Tests a nutrition plan with or without exercise during chemotherapy for pancreatic cancer
Tests a nutrition plan, with or without resistance training, in adults with pancreatic cancer.
Plain-language title generated from the registry record
Registry title: Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial)
Key facts
- Where
- Dublin, IrelandSee the site
Where in Ireland
- St Vincent's University HospitalDublin, IrelandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Cancer Trials Ireland
- Trial code
- NCT06149546
- Record updated
- 8 July 2025
- Original description
The study will examine if a multi-modal nutritional care package, with or without resistance training delivered with neoadjuvant chemotherapy, is effective at preventing loss of muscle strength during neoadjuvant chemotherapy for pancreatic cancer. There are two arms in this study: Control Arm will receive standard dietetic care and be prescribed standard pancreatic enzyme replacement therapy and oral nutritional supplement drinks with their neoadjuvant chemotherapy. The intervention Arm will have 3 additional dietitian visits and 6 physiotherapist visits that the control group will not.Read full original descriptionShow less
Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial)
The study will examine if a multi-modal nutritional care package, with or without resistance training delivered with neoadjuvant chemotherapy, is effective at preventing loss of muscle strength during neoadjuvant chemotherapy for pancreatic cancer. There are two arms in this study: Control Arm will receive standard dietetic care and be prescribed standard pancreatic enzyme replacement therapy and oral nutritional supplement drinks with their neoadjuvant chemotherapy. The intervention Arm will have 3 additional dietitian visits and 6 physiotherapist visits that the control group will not.
Inclusion: Ability to give signed informed consent and willing and able to comply with the protocol; Patients aged 18 years and above; Patients with newly diagnosed, pathologically confirmed pancreatic ductal adenocarcinoma who will undergo neoadjuvant chemotherapy following formal MDT assessment at St Vincent's University Hospital, specifically FOLFIRINOX or Gemcitabine with Nab-Paclitaxel (and/or any additional therapy regimen approved by NCCP); Patients have CT scan available and suitable for body composition analysis within 8 weeks prior to randomisation; Patients have adequate upper limb dexterity to allow assessment of hand grip strength.
Exclusion: Patient with any significant history of non-compliance to medical treatments or with inability to grant reliable informed consent; Patients who can/will not consume fish and pork products due to allergy, intolerance, religious beliefs, or dietary preferences; Patients with known blood clotting disorders, e.g antiphospholipid syndrome, factor V Leiden syndrome, haemophilia /any liver disease which has progressed to liver cirrhosis where prolonged fish oil supplementation is unsafe; Patients with uncontrolled hypertension (BP >180/110 mm Hg) which prohibits exercise; Patients with muscle wasting disorders, e.g. paraplegia, motor neuron disease, Duchenne muscular dystrophy, multiple sclerosis; Patients who are unable to consume oral diet and require prolonged enteral and/or parenteral nutritional support; Women who are pregnant or breastfeeding due to differing nutritional needs and macronutrient metabolism.